Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
Intravenous (IV) ketamine is effective in adults resistant to depression. The response was similar to that seen in younger patients, two new studies show.
Read Full NewsPaul Melmeyer, MPP, executive vice president, public policy and advocacy, Muscular Dystrophy Association, explains how adding Duchenne muscular dystrophy to the Recommended Unified Screening Panel reshapes early diagnosis, treatment timing, and family counseling.
The HCPFive: Top News for Healthcare Providers from the Week of 01/11
1.
Immune cell homing hydrogel-based platform captures dendritic cells to process mRNA from cancer vaccines
2.
No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says
3.
Pollution exposure may affect lung cancer in women who have never smoked
4.
The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.
5.
Dense breasts: What it means and what women can do about screening
1.
Breakthroughs in Cancer Care: From Rare Diagnoses to Advanced and Early-Stage Treatments
2.
Understanding Extramammary Paget's Disease: Causes, Symptoms and Treatment Options
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Exploring the Latest Advances in PTLD Cancer Treatment
5.
Uncovering the Subtle Signs of Prostate Cancer: Early Detection is Key
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
3.
Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
5.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge